<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860158</url>
  </required_header>
  <id_info>
    <org_study_id>HOG GU07-124</org_study_id>
    <nct_id>NCT00860158</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer</brief_title>
  <official_title>A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noah Hahn, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will investigate the activity of dasatinib plus LHRH analogue therapy in high-risk
      localized prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multi-center study.

        -  Dasatinib -100 mg administered once daily per oral route for 28 consecutive days.

        -  Leuprolide acetate - 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7
           days).

      The 28 days of dasatinib and leuprolide injection (plus the time required to recover from
      toxicity if encountered) is defined as a cycle. Patients will be treated for up to a maximum
      of 3 cycles of dasatinib and leuprolide acetate.

      Radical Prostatectomy should be performed no sooner than 8 hours but preferably within 24
      hours of the last administered dasatinib dose. All attempts should be made for the patient to
      have their surgery after 8 hours but within 24 hours of their last dose of dasatinib. If
      surgery delay is imperative, dasatinib therapy should continue until at least 24 hours before
      planned surgery.

      Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

      Hematopoietic:

        -  Hemoglobin (Hgb) ≥ 8.0 g/dL

        -  Platelets ≥ 100 K/mm3

        -  Absolute neutrophil count (ANC) ≥ 1.0 K/mm3

      Hepatic:

        -  Total bilirubin &lt; 2.0 X Upper Limit Normal (ULN)

        -  Aspartate aminotransferase (AST) &lt; 2.5 X ULN

        -  Alanine aminotransferase (ALT) &lt; 2.5 X ULN

      Renal:

        -  Calculated creatinine clearance of ≥ 60 cc/min using the Cockcroft-Gault formula

      Cardiovascular:

        -  No uncontrolled angina, congestive heart failure or myocardial infarction within 6
           months prior to registration for protocol therapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual; closed by funder
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Estimate the Pathologic Complete Response (pCR) Rate</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Estimate Partial Pathologic Responses (pPR)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Estimate PSA Response Rate</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Estimate Progression Free Survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Impact of Dasatinib Plus LHRH on Expression of Selected Biomarkers</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Estimate Safety and Tolerability of LHRH Plus Dasatinib</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm Assignment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant dasatinib plus leuprolide acetate followed by radical prostatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Dasatinib 100 mg administered once daily per oral route for 28 consecutive days</description>
    <arm_group_label>Single Arm Assignment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate (LHRH Analogue)</intervention_name>
    <description>Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).</description>
    <arm_group_label>Single Arm Assignment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical Prostatectomy</intervention_name>
    <description>Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.</description>
    <arm_group_label>Single Arm Assignment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate.

          -  Clinical stage T1-T3a disease.

          -  Must be willing to have a tumor biopsy, if previous tumor tissue unavailable for tumor
             marker analysis.

          -  Kattan pre-operative nomogram-predicted (based on stage, Prostate Specific Antigen
             (PSA) and Gleason score) 5-year risk of recurrence-free survival of 80% or less

          -  Must be deemed eligible for radical prostatectomy.

          -  Must be willing to use an effective method of contraception (hormonal or barrier
             method of birth control; abstinence) from the time consent is signed until 6 weeks
             after treatment discontinuation.

          -  Written informed consent and HIPAA authorization for release of personal health
             information.

          -  Age &gt; 18 years at the time of consent.

        Exclusion Criteria:

          -  No evidence of regional, lymph node or distant metastasis on clinical or radiological
             assessments. All baseline radiology studies must be performed within 28 days prior to
             registration for protocol therapy.

          -  No prior malignancy in the past 2 years except for basal cell and squamous cell
             carcinoma of the skin. Other cancers with low potential for metastasis, such as in
             situ cancers (e.g., Grade 1, TA TCC (low grade superficial bladder cancer), and
             colonic polyp with focus of adenocarcinoma) can be enrolled after approval from the
             Sponsor Investigator.

          -  No prior hormonal therapy with the exception of oral 5-alpha-reductase inhibitors
             (finasteride, dutasteride, etc.). Patients who have received prior oral anti-androgen
             therapies (bicalutamide, flutamide, nilutamide, etc.), prior LHRH agonist therapy
             (leuprolide, goserelin acetate, etc.), or prior orchiectomy are ineligible.

          -  No prior systemic chemotherapy or radiotherapy for prostate cancer is allowed.
             Transurethral resection of the prostate for benign prostatic hypertrophy (BPH) and
             oral alpha-blockers (terazosin, tamsulosin, doxazosin) are permitted.

          -  No history of hemorrhage or thrombotic events (cerebrovascular accident, deep vein
             thrombosis, pulmonary embolism, etc.) within 6 months prior to registration for
             protocol therapy.

          -  No history of diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)

          -  No history of diagnosed acquired bleeding disorder within one year (e.g., acquired
             anti-factor VIII antibodies) of registration on protocol therapy.

          -  No history of ongoing or recent (≤ 3 months of registration on protocol therapy)
             significant gastrointestinal bleeding

          -  No ongoing anti-coagulation and/or anti-platelet therapies allowed.

          -  No unresolved pleural or pericardial effusion of any grade within 3 months of
             registration for protocol therapy.

          -  No uncontrolled angina, congestive heart failure or MI within 6 months prior to
             registration for protocol therapy.

          -  No diagnosed congenital long QT syndrome.

          -  No history of clinically significant ventricular arrhythmias (such as ventricular
             tachycardia, ventricular fibrillation, or Torsades de Pointes).

          -  No prolonged QTc interval on pre-entry electrocardiogram (&gt; 450 msec)

          -  Following medications must be discontinued at least 7 days prior to registration for
             protocol therapy and be withheld for the duration of dasatinib therapy:

          -  Drugs that are generally accepted to have a risk of causing Torsades de Pointes

          -  Patient must not be receiving any prohibited CYP3A4 inhibitors /inducers/ substrates

          -  Anti-coagulation and/or anti-platelet therapies - to avoid potential bleeding risks.

          -  No major surgical procedure, open biopsy, or significant trauma within 28 days prior
             to registration for protocol therapy.

          -  Ability to comply with study and/or follow-up procedures and requirements.

          -  No treatment with any investigational agent for any medical condition within 28 days
             prior to registration for protocol therapy.

          -  No clinically significant infections or any other condition which, in the
             investigator's opinion, deems the patient an unsuitable candidate to receive the study
             drug.

          -  Ability to take oral medication (dasatinib must be swallowed whole).

          -  No known history of hypokalemia that cannot be corrected prior to registration on
             protocol therapy.

          -  No known history of hypomagnesemia that cannot be corrected prior to registration on
             protocol therapy.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noah Hahn, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hoosier Cancer Research Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical &amp; Surgical Specialists, LLC</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hoosieroncologygroup.org</url>
    <description>Hoosier Oncology Group Homepage</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2009</study_first_submitted>
  <study_first_submitted_qc>March 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2009</study_first_posted>
  <results_first_submitted>January 7, 2016</results_first_submitted>
  <results_first_submitted_qc>January 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 5, 2016</results_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hoosier Cancer Research Network</investigator_affiliation>
    <investigator_full_name>Noah Hahn, M.D.</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental Arm</title>
          <description>Neoadjuvant dasatinib plus leuprolide acetate followed by radical prostatectomy
Dasatinib: Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
Leuprolide Acetate (LHRH Analogue): Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
Radical Prostatectomy: Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Terminated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental Arm</title>
          <description>Neoadjuvant dasatinib plus leuprolide acetate followed by radical prostatectomy
Dasatinib: Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
Leuprolide Acetate (LHRH Analogue): Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
Radical Prostatectomy: Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Estimate the Pathologic Complete Response (pCR) Rate</title>
        <time_frame>18 months</time_frame>
        <population>No participants were analyzed for pCR due to study termination</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Assignment</title>
            <description>Neoadjuvant dasatinib plus leuprolide acetate followed by radical prostatectomy
Dasatinib: Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
Leuprolide Acetate (LHRH Analogue): Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
Radical Prostatectomy: Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.</description>
          </group>
        </group_list>
        <measure>
          <title>To Estimate the Pathologic Complete Response (pCR) Rate</title>
          <population>No participants were analyzed for pCR due to study termination</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Estimate Partial Pathologic Responses (pPR)</title>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Assignment</title>
            <description>Neoadjuvant dasatinib plus leuprolide acetate followed by radical prostatectomy
Dasatinib: Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
Leuprolide Acetate (LHRH Analogue): Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
Radical Prostatectomy: Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.</description>
          </group>
        </group_list>
        <measure>
          <title>To Estimate Partial Pathologic Responses (pPR)</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Estimate PSA Response Rate</title>
        <time_frame>18 months</time_frame>
        <population>Data for this secondary objective was not collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Assignment</title>
            <description>Neoadjuvant dasatinib plus leuprolide acetate followed by radical prostatectomy
Dasatinib: Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
Leuprolide Acetate (LHRH Analogue): Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
Radical Prostatectomy: Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.</description>
          </group>
        </group_list>
        <measure>
          <title>To Estimate PSA Response Rate</title>
          <population>Data for this secondary objective was not collected or analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Estimate Progression Free Survival</title>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Assignment</title>
            <description>Neoadjuvant dasatinib plus leuprolide acetate followed by radical prostatectomy
Dasatinib: Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
Leuprolide Acetate (LHRH Analogue): Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
Radical Prostatectomy: Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.</description>
          </group>
        </group_list>
        <measure>
          <title>To Estimate Progression Free Survival</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Impact of Dasatinib Plus LHRH on Expression of Selected Biomarkers</title>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Assignment</title>
            <description>Neoadjuvant dasatinib plus leuprolide acetate followed by radical prostatectomy
Dasatinib: Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
Leuprolide Acetate (LHRH Analogue): Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
Radical Prostatectomy: Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Impact of Dasatinib Plus LHRH on Expression of Selected Biomarkers</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Estimate Safety and Tolerability of LHRH Plus Dasatinib</title>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Assignment</title>
            <description>Neoadjuvant dasatinib plus leuprolide acetate followed by radical prostatectomy
Dasatinib: Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
Leuprolide Acetate (LHRH Analogue): Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
Radical Prostatectomy: Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.</description>
          </group>
        </group_list>
        <measure>
          <title>To Estimate Safety and Tolerability of LHRH Plus Dasatinib</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Arm Assignment</title>
          <description>Neoadjuvant dasatinib plus leuprolide acetate followed by radical prostatectomy
Dasatinib: Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
Leuprolide Acetate (LHRH Analogue): Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
Radical Prostatectomy: Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAEv3</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>TASTE ALTERATION (DYSGEUSIA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE (ASTHENIA, LETHARGY, MALAISE)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated due to slow accrual and no results were analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>Hoosier Cancer Research Network, Inc.</organization>
      <phone>317-921-2050</phone>
      <email>jsmith@hoosiercancer.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

